Today's Breaking News
- Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg
- Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis
- Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma
Latest R&D and Business News
- Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
- Lightlake Therapeutics’ Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
- FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Nordion Enters into Agreement to Divest Targeted Therapies Business to BTG plc
- Karolinska Development AB (publ): First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorder
- Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer
- Arsanis Nominates Preclinical Candidate for Staphylococcus aureus Program
- Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
- Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
- Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
- Perosphere Receives FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation Therapies including Factor Xa- and IIa-Inhibitors
- Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures